Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

EnBrace HR for Premenstrual Syndrome (PMS) With Prominent Mood Symptoms (or Menstrual Related Mood Disorders, MRMD)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04123483
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:27.552678+00:00
Published At
2020-01-02T00:00:00+00:00
Record Updated At
2020-01-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Premenstrual Syndrome", "Premenstrual Dysphoric Disorder", "Premenstrual Tension", "Menstrual Related Mood Disorder"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-01-02"
protocolSection.identificationModule.nctId
"NCT04123483"
protocolSection.identificationModule.officialTitle
"EnBrace HR for Premenstrual Syndrome (PMS) With Prominent Mood Symptoms (or Menstrual Related Mood Disorders, MRMD)"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Premenstrual Syndrome (protocolSection.conditionsModule.conditions)
  • Premenstrual Dysphoric Disorder (protocolSection.conditionsModule.conditions)
  • Premenstrual Tension (protocolSection.conditionsModule.conditions)
  • Menstrual Related Mood Disorder (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.